Efficient ex vivo generation of dendritic cells from CD14+ blood monocytes in the presence of human serum albumin for use in clinical vaccine trials

British Journal of Haematology

Volumn 114, Issue 3, 2001, Pages 681-689

  Araki, Hiroto ^a   Katayama, Naoyuki ^a   Mitani, Hidetsugu ^a   Suzuki, Hirohito ^a   Nishikawa, Hiroyoshi ^a   Masuya, Masahiro ^a   Ikuta, Yasushi ^a   Hoshino, Natsuki ^a   Miyashita, Hiroyuki ^a   Nishii, Kazuhiro ^a   Minami, Nobuyuki ^b   Shiku, Hiroshi ^a  

^a MIE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b MIE UNIVERSITY HOSPITAL   (Japan)

Author keywords

Dendritic cell; HER2 peptide; Human serum albumin; Monocyte; Serum free

Indexed keywords

CANCER VACCINE; CD1 ANTIGEN; CD14 ANTIGEN; COLONY STIMULATING FACTOR 1; DEXTRAN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HUMAN SERUM ALBUMIN; INTERLEUKIN 4; MAJOR HISTOCOMPATIBILITY ANTIGEN; PEPTIDE; TUMOR REJECTION ANTIGEN; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ARTICLE; BLOOD; BLOOD AUTOTRANSFUSION; CELL COUNT; CELL CULTURE; CELL DIFFERENTIATION; CELL SPECIFICITY; CONTROLLED STUDY; CYTOTOXICITY; DENDRITIC CELL; DRUG SCREENING; DRUG UPTAKE; HUMAN; HUMAN CELL; IMMUNOTHERAPY; MONOCYTE; PRIORITY JOURNAL; T LYMPHOCYTE; TIME;

ANTIGENS, CD14; CANCER VACCINES; CELL CULTURE TECHNIQUES; CELL DIFFERENTIATION; DENDRITIC CELLS; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INTERLEUKIN-4; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE ACTIVATION; RECEPTOR, ERBB-2; SERUM ALBUMIN; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0034791610     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2001.02973.x     Document Type: Article

References (38)

1. T cell priming versus T cell tolerance induced by synthetic peptides
2. Dendritic cells and the control of immunity
3. Immunobiology of dendritic cells
4. Improved methods for the generation of dendritic cells from nonproliferating progenitors in human blood
5. From defined human tumor antigens to effective immunization?
6. Recent advances in the study of dendritic cells and follicular dendritic cells
7. Origin, maturation and antigen presenting function of dendritic cells
8. + T cells in vitro
9. Distinct subsets of dendritic cells resembling dermal DCs can be generated in vitro from monocytes, in the presence of different serum supplements
10. Reversal of tolerance to human MUC1 antigen in MUC1 transgenic mice immunized with fusions of dendritic and carcinoma cells
11. Dendritic cells: Unique leukocyte populations which control the primary immune response
12. Cancer antigens: Immune recognition of self and altered self
13. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells
14. + cytotoxic T lymphocytes
15. Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions
16. Idiotypic protein-pulsed dendritic cell vaccination in multiple myeloma
17. + hematopoietic progenitor cells
18. Activity of interleukin 6 in the differentiation of monocytes to macrophages and dendritic cells
19. + selected blood progenitor cells of myeloma patients, cultured in serum-free media, do not contain the Kaposi sarcoma herpesvirus genome
20. A phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen
21. Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen
22. Peptides derived from a wild-type murine proto-oncogene c-erbB-2/HER2/neu can induce CTL and tumor suppression in syngeneic hosts
23. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells
24. A novel human HER2-derived peptide homologous to the mouse Kd-restricted tumor rejection antigen can induce HLA-A24-restricted cytotoxic T lymphocytes in ovarian cancer patients and healthy individuals
25. Cancer vaccines
26. Functional and phenotypic characteristics of dendritic cells generated in human plasma supplemented medium
27. The CD1 Systems: Antigen-presenting molecules for T cell recognition of lipids and glycolipids
28. Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma: A feasibility study
29. Generation of mature dendritic cells from human blood: An improved method with special regard to clinical applicability
30. + blood progenitors for anticancer therapy
31. The dendritic cell system and its role in immunogenicity
32. T lymphocytes recognition of human group 1, CD1 molecules: Implications for innate and acquired immunity
33. Extensive characterization of dendritic cells generated in serum-free conditions: Regulation of soluble antigen uptake, apoptotic tumor cell phagocytosis, chemotaxis and T cell activation during maturation in vitro
34. Vaccination with Mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma
35. Vaccination of multiple myeloma patients with idiotype-pulsed dendritic cells: Immunological and clinical aspects
36. Enhanced tumor growth after peptide vaccination: Functional deletion of tumor-specific CTL induced by peptide vaccination can lead to the inability to reject tumors
37. Enhancement of tumor outgrowth through CTL tolerization after peptide vaccination is avoided by peptide presentation on dendritic cells
38. T cell defined tumor antigens